Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медрейх ЛімітедfiledCriticalМедрейх Лімітед
Priority to UAA201109989ApriorityCriticalpatent/UA105513C2/en
Publication of UA105513C2publicationCriticalpatent/UA105513C2/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The invention relates to medicine and represents a glucosamine or its salts prolonged release dosage form containing a combination of hydroxypropyl methylcellulose of molecular weight 100,000 and hydroxypropyl methylcellulose of molecular weight 200,000 as a delayed release agent, and one or more pharmaceutically acceptable excipients, wherein glucosamine and its salts are found partially in an intragranular form and partially in an extragranular form.
UAA201109989A2011-08-122011-08-12Glucosamine prolonged release dosage form
UA105513C2
(en)
Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
Pharmaceutical composition in the form of tablets comprising gastrointestinal microgranules containing 100 to 800 mg of rifaximin, up to 30% w / w extragranular excipients and a film-forming coating; and use to treat an infectious and / or inflammatory bowel disease, such as crohn's disease.
NEW PHARMACEUTICAL FORMULATIONS SUITABLE FOR ORAL ADMINISTRATION OF DIHYDRATE ESOMEPRAZOLE MAGNESIUM, IN THE FORM OF MUPS TABLETS (MULTI UNIT PELLETS SYSTEM).